Ingredient Guide

Yohimbine: Benefits, Dosage, and What the Research Says

Name: Yohimbine: Benefits, Dosage, and What the Research Says
Creator: Jessica Medson
Published: 2026-07-17

What the clinical evidence actually shows - and why the safety profile demands serious attention

Men's HealthEvidence: Human observational studies

Published July 17, 2026Last updated July 17, 20269 min read

Yohimbine is an indole alkaloid derived from the bark of Pausinystalia yohimbe, a West African tree, that works primarily as an alpha-2 adrenergic receptor antagonist - removing the feedback brake on norepinephrine release and promoting free fatty acid mobilization from adipose tissue. A 2021 meta-analysis of 8 randomized controlled trials (460 patients) found yohimbine monotherapy produced an odds ratio of 2.08 for erectile function improvement versus placebo (p=0.002), while fat-loss evidence is more mixed: one small 21-day RCT in lean soccer players found a 2.2 percentage point body fat reduction at 20 mg/day, but two larger placebo-controlled trials in non-athletic adults found no significant effect. Yohimbine carries a clinically meaningful safety profile - raising blood pressure and heart rate, reliably inducing anxiety, and posing a potentially life-threatening interaction with monoamine oxidase inhibitors - and is not appropriate for general population use without medical supervision.

Key Takeaways

Yohimbine is an alpha-2 adrenergic receptor antagonist derived from Pausinystalia yohimbe bark that increases norepinephrine levels and promotes fat cell lipolysis, particularly in the fasted state.
A 2021 meta-analysis of 8 randomized controlled trials found yohimbine improved erectile function with an odds ratio of 2.08 versus placebo (p=0.002), with the strongest evidence for psychogenic causes.
Fat-loss evidence is mixed and population-dependent: a positive signal appeared in lean, exercising athletes (one RCT), but two placebo-controlled trials in overweight or non-athletic adults found no significant benefit.
Clinical research doses range from 5.4 mg three times daily for sexual health support to 20 mg/day in divided doses in athletic body composition studies; the fat-mobilizing effect is abolished when taken with food.
HIGH RISK: Yohimbine raises blood pressure and heart rate, reliably causes anxiety and palpitations, and carries a potentially life-threatening interaction with MAOIs. It is contraindicated in hypertension, cardiovascular disease, and anxiety disorders.

What Is Yohimbine?

Yohimbine is an indole alkaloid extracted from the bark of Pausinystalia yohimbe (also known as Corynanthe yohimbe), a tall evergreen tree native to the rainforests of Central and West Africa. Yohimbe bark has been used in West African traditional medicine for centuries as a stimulant and aphrodisiac. In the 20th century, yohimbine was isolated as the primary bioactive compound and characterized pharmacologically, leading to its prescription use in some countries for erectile dysfunction under trade names such as Yocon.¹

In the United States today, yohimbine is sold primarily as an over-the-counter dietary supplement in two forms: purified yohimbine hydrochloride (yohimbine HCl) at a stated milligram dose, and crude yohimbe bark extract at a stated weight of plant material. These are not interchangeable. Crude bark extracts vary dramatically in actual yohimbine alkaloid content, and a significant portion of commercial yohimbe products are mislabeled. Standardized yohimbine HCl products with a declared milligram dose are the only form that allows meaningful dose control.

Key facts at a glance

Botanical source: Bark of Pausinystalia yohimbe, a West African evergreen
Active compound: Yohimbine (an indole alkaloid); yohimbine HCl is the purified salt form used in clinical trials
Drug class: Alpha-2 adrenergic receptor antagonist; sympathomimetic
Primary marketed uses: Male sexual health support, fat loss support, athletic performance
US regulatory status: Sold as an unregulated dietary supplement; no current FDA-approved drug application for the supplement form

How Does Yohimbine Work?

Yohimbine's primary, well-characterized mechanism is competitive antagonism at alpha-2 adrenergic receptors - specifically the alpha-2A, alpha-2B, and alpha-2C subtypes.¹ Under normal physiology, these receptors serve as a negative feedback brake: when activated by norepinephrine (NE), they signal the nerve terminal to reduce further NE release, and they suppress lipolysis (fat breakdown) within adipose tissue. Yohimbine competes with NE at these receptor sites, blocking that brake.

The downstream result is a predictable package of sympathetic activation. Plasma norepinephrine concentrations increase by approximately 40-100% in fasting humans,²³ free fatty acids and glycerol are released from fat cells into the bloodstream, and heart rate and blood pressure typically rise. These are pharmacological class effects - expected, not idiosyncratic.

Secondary receptor targets

Yohimbine also has meaningful affinity for serotonin receptors (partial agonist at 5-HT1A; antagonist at 5-HT1B and 5-HT1D), dopamine D2 receptors (antagonist), and imidazoline receptors.¹ These secondary actions contribute to yohimbine's stimulant and anxiogenic properties and help explain its documented ability to trigger anxiety and panic - effects that are pharmacologically predictable rather than rare reactions.

The alpha-2 receptor and resistant fat depots

Alpha-2 adrenergic receptors are particularly concentrated in fat depots that tend to resist weight loss - including the lower abdomen, hips, and thighs. The theoretical rationale for yohimbine is that blocking these receptors might preferentially promote fat mobilization from these areas. This hypothesis is pharmacologically plausible, but direct evidence from human imaging studies is limited.

Critical timing: food abolishes the effect

Human research consistently shows that yohimbine's fat-mobilizing effect requires a fasted state. In a controlled pharmacology study, the lipid-mobilizing response was completely suppressed after eating and was enhanced during fasted exercise.² Taking yohimbine in a fed state is likely to blunt its primary mechanism of action on fat tissue.

Yohimbine and Fat Mobilization: What the Research Shows

Fat loss is the most commonly marketed benefit of yohimbine supplements. The clinical picture is genuinely mixed, with results differing substantially based on study population, baseline body composition, and conditions of use. Honest interpretation of this evidence is important for both accuracy and FTC compliance.

Acute fat mobilization in humans

The pharmacological effect of yohimbine on fat release is well-established in short-term human studies. In a controlled study of healthy fasting men, oral yohimbine at approximately 0.2 mg/kg raised plasma glycerol and non-esterified fatty acids (NEFA) significantly, with plasma norepinephrine increasing approximately 40-50%.² A parallel study in women - including both normal-weight and obese participants - confirmed similar lipid mobilization, with plasma norepinephrine nearly doubling following yohimbine administration.³ Both studies documented that this response was attenuated or fully abolished in the fed state and partially blocked by beta-blocker pretreatment, confirming that the mechanism operates through increased norepinephrine-driven lipolysis.

Body fat outcomes in lean, trained athletes

The most-cited positive body composition RCT enrolled 20 professional male soccer players in a 21-day, double-blind, placebo-controlled trial.⁴ Participants supplementing with 20 mg yohimbine daily (two 10 mg doses) experienced a statistically significant decrease in body fat percentage - from 9.3% to 7.1% (p<0.05) - while the placebo group showed no change. Body mass, muscle mass, and performance metrics (sprint time, vertical jump) were not significantly different between groups. This is a meaningful signal from a single small RCT in an already-lean, highly active population.

Null results in non-athletic and overweight adults

Evidence from general populations is less encouraging. A rigorous 6-month double-blind RCT in 47 men (mean age 42) randomized to peak doses of 43 mg/day yohimbine or placebo found no significant effect on any measured variable - including body weight, BMI, body fat percentage, fat distribution by CT scan, or blood lipid levels.⁵ An 8-week study in 19 obese individuals following a 1,000 kcal/day hypocaloric diet similarly found no significant difference between the yohimbine group (18 mg/day) and placebo in body weight, lipid parameters, blood pressure, or heart rate.⁶

A hypothesis paper proposed that pre-exercise yohimbine administration could enhance exercise-based fat loss by increasing free fatty acid availability during and after training,¹³ but this remains a mechanistic rationale rather than a confirmed outcome in a dedicated human trial.

Practical interpretation

Clinical research suggests yohimbine may support fat mobilization acutely in a fasted state - a signal most relevant to already-lean, physically active individuals. The available evidence does not support yohimbine as a meaningful fat loss supplement for overweight or sedentary adults, and two placebo-controlled trials in that population found no benefit even at high doses over extended periods.

Yohimbine and Erectile Function: What the Research Shows

Among yohimbine's studied applications, erectile function support has the strongest and most consistent body of clinical evidence - particularly for cases where psychological factors are the primary driver.

Landmark randomized controlled trial

A 10-week double-blind, placebo-controlled RCT published in The Lancet enrolled 48 men with psychogenic impotence and randomized them to either 18 mg/day yohimbine (in divided doses) or placebo.⁷ Results showed that 62% of the yohimbine group reported some improvement in sexual function, compared with 16% of the placebo group (p<0.05). Researchers concluded that yohimbine appeared effective for psychogenic impotence.

Systematic review and meta-analysis

A 2021 systematic review and meta-analysis by Wibowo et al. pooled 8 randomized controlled trials comprising 460 patients with erectile dysfunction.⁸ Yohimbine monotherapy produced significantly greater improvement in erectile function compared with placebo (odds ratio 2.08; 95% CI 1.30-3.32; p=0.002). When yohimbine was combined with other agents, the effect was larger (OR 6.35), though this reflects combination therapy rather than yohimbine alone. A narrative review by Morales drawing on earlier meta-analyses similarly concluded that yohimbine shows a consistent advantage over placebo across multiple analyses.⁹

Limitations and context

Evidence for organic (physically caused) erectile dysfunction - arising from vascular disease, diabetes, or nerve damage - is more limited and variable. The constituent trials in existing meta-analyses are older and methodologically heterogeneous. Yohimbine has not been compared head-to-head with FDA-approved PDE5 inhibitors (sildenafil, tadalafil, vardenafil) in adequately powered trials. Men seeking treatment for erectile dysfunction should consult a physician to evaluate the underlying cause and discuss all evidence-based options.

Safety, Side Effects, and Drug Interactions

Yohimbine has a clinically meaningful risk profile and is not appropriate for all adults. It is one of the few dietary supplement ingredients with well-documented, dose-related cardiovascular and psychiatric adverse effects. This section covers the most important risks. Read it in full before considering use, and consult a physician if you have any health conditions or take prescription medications.

Who should not use yohimbine

People with hypertension (high blood pressure) or any cardiovascular disease, including arrhythmia or coronary artery disease
People with anxiety disorders, panic disorder, PTSD, or bipolar disorder
People currently taking or recently stopped taking MAOIs (phenelzine, tranylcypromine, selegiline, isocarboxazid)
People taking antihypertensive medications (yohimbine may reduce their effectiveness)
Pregnant or breastfeeding individuals (no safety data; avoid)
Children and adolescents
People with kidney or liver disease

Cardiovascular effects

Yohimbine raises both systolic blood pressure and heart rate as a direct, expected consequence of its mechanism - amplifying norepinephrine signaling in the cardiovascular system. These effects are documented across multiple controlled studies involving healthy volunteers and clinical populations.¹⁰¹¹ A retrospective review of 238 adverse events reported to the California Poison Control System over seven years (2000-2006) found hypertension in 25% of cases and tachycardia in 43%.¹² At doses above the therapeutic range, cardiac arrhythmias and myocardial infarction have been documented in case reports.¹

Anxiety and panic (documented in controlled studies)

Yohimbine reliably induces anxiety, nervousness, palpitations, and restlessness by increasing central and peripheral norepinephrine activity. In a controlled study involving 39 patients with panic disorder and 20 healthy controls, panic disorder patients experienced significantly greater anxiety, hot and cold flashes, tremors, piloerection, and systolic blood pressure increases compared to controls (p<0.05).¹¹ A separate study found that yohimbine triggered full panic attacks meeting DSM diagnostic criteria in 6 of 11 panic disorder patients - but in none of the healthy control subjects.¹⁰ People with any anxiety disorder should not use yohimbine.

MAOI interaction - potentially life-threatening

Combining yohimbine with monoamine oxidase inhibitors - including phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Emsam, Zelapar), and isocarboxazid (Marplan) - can trigger a potentially life-threatening hypertensive crisis through additive elevation of norepinephrine and other catecholamines. This combination must be strictly avoided. Consult your physician about the required washout period before any yohimbine use after stopping an MAOI.

Other drug interactions

Antihypertensives: Yohimbine may reduce the blood-pressure-lowering effect of beta-blockers, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers.
Stimulants and caffeine: Additive effects on heart rate and blood pressure.
Antidepressants: Tricyclic antidepressants and SNRIs that affect noradrenergic pathways may interact unpredictably; discuss with your prescriber.

Highly variable individual response

A 2024 comprehensive review identified a 22-fold difference in blood yohimbine concentrations among individuals receiving the same dose, driven by genetic variation in the CYP2D6 enzyme responsible for yohimbine metabolism.¹ Poor CYP2D6 metabolizers may accumulate dangerously high blood levels at doses that are well-tolerated by typical metabolizers. This metabolic variability, combined with widespread mislabeling of OTC yohimbe bark products, makes dose prediction particularly unreliable for the supplement form.

Adverse event profile from real-world data

The California Poison Control System review of 238 yohimbine-related adverse events found the most common effects were gastrointestinal distress (46%), tachycardia (43%), anxiety or agitation (33%), and hypertension (25%).¹² Notably, 98.7% of cases involved OTC herbal products rather than prescription-grade yohimbine, and yohimbine exposures required healthcare facility management more frequently than typical supplement exposures.

Bottom Line

Yohimbine is a pharmacologically active ingredient with documented mechanisms and real clinical data - but also a narrow therapeutic window and a risk profile that is atypical for a dietary supplement.

Best-supported use: Erectile function support in men with psychogenic (non-physical) causes - where a meta-analysis of 8 RCTs and multiple individual trials show statistically significant, consistent improvement versus placebo.
Conditional evidence for fat mobilization: Research suggests yohimbine may support fat mobilization in fasted, exercising, already-lean individuals - but evidence does not support it as a general weight loss supplement for overweight adults.
Two well-controlled trials in non-athletic adults found no benefit on body weight, fat distribution, or metabolic markers at doses up to 43 mg/day over six months.
High-risk profile: Yohimbine raises blood pressure and heart rate, reliably induces anxiety, and carries a potentially life-threatening interaction with MAOIs. These are not rare reactions - they are pharmacologically expected consequences of its mechanism.

If you are considering a yohimbine supplement, discuss it with your physician - particularly if you take any prescription medications, have a personal or family history of cardiovascular or psychiatric conditions, or are sensitive to stimulants. The 22-fold variation in individual blood-level response means that a dose another person tolerates well may be excessive for you.

Yohimbine Dosage: What Clinical Trials Used

The following doses are drawn directly from the cited clinical trials. They describe what researchers studied, not universal recommendations. Individual response to yohimbine varies dramatically (up to 22-fold in measured blood concentrations); start at the lowest dose and use only under medical supervision if you have any health conditions.

Goal	Typical Dose	Timing	Notes
Erectile function support	5.4 mg three times daily (18 mg total per day)	Regular daily schedule; food timing less critical for this endpoint	Dose used in the Reid et al. (1987) Lancet RCT and consistent with historic prescription-grade Yocon dosing. Consult a physician before use.
Body composition support in lean, trained athletes	20 mg/day in two equal doses (10 mg twice daily)	Fasted state, ideally before exercise; effect is abolished after eating	Dose from Ostojic (2006) RCT in professional soccer players. Not established in overweight or sedentary individuals - two trials at comparable or higher doses in non-athletes found no benefit.
Acute fat mobilization (pharmacology research dose)	Approximately 0.2 mg/kg body weight (roughly 14 mg for a 70 kg individual)	Fasted state only; combined with exercise to maximize response	Dose from Galitzky et al. (1988) human study showing elevated plasma NEFA and glycerol. This is a pharmacological endpoint (fat release into blood), not a body fat outcome dose.

These doses reflect research protocols, not universal recommendations. Yohimbine's narrow therapeutic window and wide interindividual variability in metabolism (CYP2D6 phenotype) mean that a dose tolerated by one person may be excessive for another. Never exceed doses used in clinical trials without direct physician supervision.

What the Evidence Shows at a Glance

A summary of the clinical evidence by outcome, based on verified human trial data.

Outcome	What studies show	Evidence strength
Body fat reduction - lean, trained athletes	21-day RCT (n=20 soccer players, 20 mg/day): body fat fell from 9.3% to 7.1% vs. no change with placebo (p<0.05)	Moderate - single small RCT in a specific population
Body fat / weight loss - general population	Two placebo-controlled RCTs (n=47 and n=19) at 18-43 mg/day over 6-8 weeks found no significant benefit over placebo	Weak - consistent null result in non-athletic adults
Acute fat mobilization (free fatty acids)	Human controlled studies consistently show elevated plasma NEFA and glycerol in fasted state; effect abolished after eating	Moderate - consistent pharmacological signal; not a fat-mass outcome
Erectile function - psychogenic ED	Meta-analysis of 8 RCTs (460 patients): OR 2.08 vs. placebo (95% CI 1.30-3.32, p=0.002); landmark RCT showed 62% vs. 16% improvement rate	Moderate - consistent benefit across trials, though trials are older and heterogeneous
Erectile function - organic ED	Evidence is limited and variable; no adequately powered head-to-head trial vs. PDE5 inhibitors exists	Weak - insufficient data to draw conclusions
Anxiety and panic induction	Multiple controlled studies confirm dose-dependent anxiety; yohimbine triggered panic attacks in 6/11 panic disorder patients vs. 0 controls	Strong - consistent, replicated safety signal
Blood pressure and heart rate elevation	Consistently documented across controlled studies; hypertension in 25% and tachycardia in 43% of real-world adverse event reports	Strong - consistent cardiovascular safety signal

OR = odds ratio. RCT = randomized controlled trial. ED = erectile dysfunction. NEFA = non-esterified fatty acids. Evidence strength ratings reflect the quantity, quality, and consistency of human clinical data - not the magnitude of effect.

Frequently Asked Questions

What is yohimbine good for?

Clinical research most consistently supports yohimbine for erectile function support, especially in men with psychogenic (non-physical) causes - a meta-analysis of 8 randomized controlled trials found a twofold greater improvement versus placebo (OR 2.08, p=0.002). Evidence for fat loss is more mixed: benefit appeared in one small RCT of lean, exercising athletes, but not in two trials involving overweight or non-athletic adults.

How much yohimbine should I take per day?

Clinical trials used 18 mg/day (5.4 mg three times daily) for erectile function support and 20 mg/day in two divided doses for body composition in athletes. Blood levels vary up to 22-fold between individuals due to differences in CYP2D6 enzyme activity, so start at the lowest possible dose and consult a physician before use - especially if you take any medications or have health conditions.

Is yohimbine safe?

Yohimbine carries a meaningful risk profile that is atypical for a dietary supplement. Even at typical doses it reliably raises blood pressure and heart rate, causes anxiety and palpitations, and can trigger panic attacks in susceptible individuals. A California Poison Control database review found tachycardia in 43% and hypertension in 25% of 238 adverse event reports. It is contraindicated with MAOIs and for people with cardiovascular or anxiety disorders.

Does yohimbine actually help with fat loss?

Evidence is modest and context-dependent. One 21-day RCT in lean, professional soccer players taking 20 mg/day found body fat dropped from 9.3% to 7.1%, but two rigorous placebo-controlled trials in non-athletic or overweight adults found no significant fat loss at doses up to 43 mg/day over 6 months. Fat-mobilizing effects in human pharmacology studies are greatest when taken fasted before exercise and are abolished in the fed state.

What does yohimbine do to blood pressure?

Yohimbine consistently raises systolic blood pressure by blocking alpha-2 receptors, which removes the brake on norepinephrine release throughout the cardiovascular system. This is a pharmacologically expected, class-level effect documented across multiple controlled studies - not a rare reaction. A poison control review found hypertension in 25% of 238 real-world yohimbine adverse event cases. Anyone with hypertension should avoid yohimbine entirely.

Can yohimbine cause anxiety or panic attacks?

Yes - this is a well-documented, pharmacologically expected effect, not a rare side effect. Multiple controlled studies confirm that yohimbine reliably induces anxiety, nervousness, palpitations, and tremors by increasing central norepinephrine activity. In a controlled study, yohimbine triggered full panic attacks meeting diagnostic criteria in 6 of 11 panic disorder patients but in none of the healthy controls. People with any anxiety disorder should not use yohimbine.

What medications interact with yohimbine?

The most dangerous interaction is with MAOIs (phenelzine, tranylcypromine, selegiline, isocarboxazid), which can cause a potentially life-threatening hypertensive crisis - this combination must be strictly avoided. Yohimbine may also blunt the effectiveness of antihypertensive drugs, produce additive cardiovascular stimulation with caffeine or other sympathomimetics, and interact with antidepressants affecting noradrenergic pathways. Always consult a physician before use if you take any prescription medications.

What is the difference between yohimbine and yohimbe?

Yohimbe refers to the bark of the Pausinystalia yohimbe tree, sold as a crude botanical extract. Yohimbine is the specific alkaloid compound within that bark - yohimbine HCl is the purified, measured salt form used in all clinical trials. OTC yohimbe bark products frequently mislabel their actual yohimbine content, making dosing unpredictable. If choosing a supplement, standardized yohimbine HCl products with a declared milligram dose offer substantially more reliable dosing control.

Should I take yohimbine on an empty stomach?

Yes, if fat mobilization is the goal - human pharmacology data show that yohimbine's free fatty acid-releasing effect is completely suppressed after eating and is enhanced during fasted exercise. In the one positive body-fat RCT (Ostojic 2006), participants took it in a fasted state before training. For erectile function support, timing relative to meals is less established. Never take yohimbine with food expecting full fat-mobilizing activity.

Is yohimbine FDA-approved?

No dietary supplement form of yohimbine or yohimbe is FDA-approved for any indication. A prescription drug form (Yocon, 5.4 mg tablets) was once marketed for erectile dysfunction, but it no longer holds a current FDA-approved new drug application. The supplement sold in stores is regulated under DSHEA - it is not evaluated by the FDA for safety or efficacy before reaching the market, and the FDA has issued safety warnings about some yohimbe-containing products.

Shop Yohimbine

HealthFare Yohimbine supplements

Yohimbine HCL 10mg 240 Capsules

From $14.95· save 10% on subscription

Shop now

Yohimbine 5mg 240 Capsules